The present meta-analysis revealed that metformin may has a certain therapeutic effect on NAFLD that short-term (no more that 6 months), low-dose (500 to 3000 mg/d) metformin could ameliorate the levels of ALT, AST, TG and TC in NAFLD patients, and significantly improve HOMA-IR finally. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.